KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $220.9 million.

  • West Pharmaceutical Services' Long-Term Investments rose 156.32% to $220.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $220.9 million, marking a year-over-year increase of 156.32%. This contributed to the annual value of $202.1 million for FY2024, which is 376.19% down from last year.
  • West Pharmaceutical Services' Long-Term Investments amounted to $220.9 million in Q3 2025, which was up 156.32% from $224.7 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Long-Term Investments registered a high of $224.7 million during Q2 2025, and its lowest value of $188.6 million during Q3 2022.
  • Over the past 5 years, West Pharmaceutical Services' median Long-Term Investments value was $208.1 million (recorded in 2022), while the average stood at $207.2 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Long-Term Investments plummeted by 1256.37% in 2022, and later skyrocketed by 1337.03% in 2025.
  • West Pharmaceutical Services' Long-Term Investments (Quarter) stood at $207.7 million in 2021, then fell by 1.35% to $204.9 million in 2022, then grew by 2.49% to $210.0 million in 2023, then fell by 3.76% to $202.1 million in 2024, then rose by 9.3% to $220.9 million in 2025.
  • Its Long-Term Investments stands at $220.9 million for Q3 2025, versus $224.7 million for Q2 2025 and $211.9 million for Q1 2025.